Adults and adolescents with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids
150-375mg SC every 2 or 4 wks. Dose is adjusted depending on the plasma level of IgE. Dose above 150mg is injected in different sites.
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
It is a monoclonal antibody that selectively binds to IgE thus inhibiting the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. This limits the degree of release of media-tors of the allergic response at the same time reducing the number of FceRI receptors on basophils in atopic patients.
Not be used for the treatment of acute bronchospasm or status asthmaticus